Year-end Sale % OFF 
Abstract
Current NM preparative regimens for allo HCT consistently cause significant post-HCT neutropenia and thrombocytopenia. To test the hypothesis that pre-HCT immunosuppression alone allows engraftment without significant myelosuppression, we are evaluating a preparative regimen of continuous-infusion PENTO (12 mg/m2 over 72 hr, days -8 through -6) and ALEM (20 mg/day, days -5 through -1) for allo HCT in high-risk patients (pts) with hematologic malignancies. To date, 5 pts (median age, 64 yr; range, 54–69 yr) with AML (3 pts), CLL (1 pt), or multiple myeloma (MM) (1 pt) have been enrolled on this trial; 2 pts (1 AML, 1 MM) had failed previous autologous HCT.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
